At Boehringer Ingelheim, “Sustainable Development – For Generations” is about a journey. One that started in 1885 and one that we hope, and believe, will never end.  Because Boehringer Ingelheim will always strive to be better: develop better therapies, enable better health care solutions and contribute to a better world. Not just now or for the next generation, but for all generations to come. Because being a family business is about family. And we consider our employees, patients, communities and business partners all to be part of that family.

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health.

Boehringer Ingelheim China headquartered in Shanghai with more than 3,800 employees. The major business focuses of Boehringer Ingelheim China includes Human Pharma, Animal Health and Biopharmaceuticals Contract Manufacturing. In recent years, the company has achieved continuous development, and has been certified as “China Top Employer” during 2014 to 2023. China is a focus market and source of innovation for Boehringer Ingelheim. China’s needs have been incorporated into the company’s global R&D strategy. The company aims to bring more and better innovative products earlier to the Chinese patients, contribute to the high-quality development of China’s healthcare industry, and comprehensively improve the health of human and animals.